
In SURMOUNT-ADOLESCENTS, tirzepatide cut BMI 18.5% at 72 weeks vs a 0.5% rise with placebo in adolescents with obesity.
Children who are overweight or obese, especially girls, face an increased risk for developing gallstone disease compared with their normal-weight peers, according to research by Kaiser Permanente Southern California.






